Forecasting is more than extrapolating a trend line. Organizations need to model the key leading indicators and outcomes for those areas where a forecast is critical to their success.

Markets & Clients | Life Sciences

Life Sciences

Organizations in the life sciences industry have been continually challenged with finding the next blockbuster pharmaceutical or breakthrough – or in many cases just to sustain profitability. Recently, licensing and acquisitions have accounted for greater than 50% of the future pipeline. For these critical activities, deal-making capabilities separate the winners from the losers. Success demands superior strategy and execution.

Value creation requires not just one myopic rifle shot, but a more shotgun-oriented portfolio approach to future success. A careful balance should exist between identifying a series of small acquisitions that provide access to key technologies and other acquisitions that complement existing pipelines.

At the same time, it has become even more critical to optimize the value of your acquired company or technology. A great deal of intellectual capital, profitability, and time to market has been lost to a poorly executed acquisition.

T2C enables this process by providing operational due diligence, portfolio evaluations, and post-deal operational optimization of an acquired company.